Suven Pharma is in the business of Contract development & manufacturing organisation (CDMO), catering to the needs of global Pharma Industry.
Financial Results:
Suven Pharmaceuticals Ltd reported Revenues for Q1FY24 of ₹348.00 Crores up from ₹339.00 Crore year on year, a rise of 2.65%.
Total Expenses for Q1FY24 of ₹195.00 Crores down from ₹201.00 Crores year on year, a fall of 2.99%.
Consolidated Net Profit of ₹121.00 Crores up 12.04% from ₹108.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹4.74, up 12.32% from ₹4.22 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.